Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’
British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2017.58
Full Text
Open PDFAbstract
Available in full text
Date
March 21, 2017
Authors
Publisher
Springer Science and Business Media LLC